JOHN KIRKWOOD to Cost-Benefit Analysis
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Cost-Benefit Analysis.
Connection Strength
0.159
-
Adjuvant therapy with high-dose interferon alpha 2b in patients with high-risk stage IIB/III melanoma. Nat Clin Pract Oncol. 2008 Jan; 5(1):2-3.
Score: 0.055
-
Update on adjuvant interferon therapy for high-risk melanoma. Oncology (Williston Park). 2002 Sep; 16(9):1177-87; discussion 1190-2, 1197.
Score: 0.038
-
Update on the role of adjuvant interferon for high risk melanoma. Forum (Genova). 2000 Jul-Sep; 10(3):230-9.
Score: 0.033
-
Economic analyses of benefit from interferon-alpha 2B in high-risk melanoma: trade-offs between completeness, simplicity and clarity. Eur J Cancer. 1997 Aug; 33(9):1345-6.
Score: 0.027
-
Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684. J Clin Oncol. 1997 Jun; 15(6):2351-8.
Score: 0.007